Table 2.

The expression profiles of ABCA2 and ABCA3, separately (A, B) and together (C) at the mRNA and protein levels in 69 patients with de novo ALL

A
ABCA2	MDR+	MDR−	Total
mRNA−, protein−	11 (19.6%)	45 (80.4%)	56
mRNA+, protein−	3 (37.5%)	5 (62.5%)	8
mRNA+, protein+	5 (100%)	0 (0%)	5
Total	19 (27.5%)	50 (72.5%)	69
B
ABCA3	MDR+	MDR−	Total
mRNA−, protein−	10 (19.2%)	42 (80.8%)	52
mRNA+, protein−	2 (22.2%)	7 (77.8)	9
mRNA+, protein+	7 (87.5%)	1 (12.5%)	8
Total	19 (27.5%)	50 (72.5%)	69
C
ABCA2 and/or ABCA3	MDR+	MDR−	Total
mRNA−, protein−	4 (9.3%)	39 (90.7%)	43
mRNA+, protein−	4 (28.5%)	10 (71.5%)	14
mRNA+, protein+	11 (91.5%)	1 (8.5%)	12
Total	19 (27.5%)	50 (72.5%)	69

Notes: mRNA⁻ indicates no overexpression of mRNA compared to the control group; protein⁻ indicates no band was observed in Western blotting.

Abbreviations: ALL, acute lymphoblastic leukemia; MDR, multidrug resistance.